Cannabis stocks surged with Tilray, Canopy Growth, and Curaleaf posting major gains after FDA announced it will ease CBD enforcement starting in 2026. The postCannabis stocks surged with Tilray, Canopy Growth, and Curaleaf posting major gains after FDA announced it will ease CBD enforcement starting in 2026. The post

FDA CBD Policy Shift Triggers Massive Rally in Cannabis Stocks

2026/04/03 18:02
3분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

Key Takeaways

  • FDA announced it will not pursue enforcement action against certain hemp-derived oral CBD products
  • The cannabis sector ETF surged 16% for the week, marking its best performance since December
  • Major players including Tilray, Canopy Growth, and Curaleaf experienced significant share price increases Thursday
  • The announcement follows President Trump’s executive order from December that moved marijuana to Schedule III classification
  • Industry experts note the policy remains limited in scope and falls short of comprehensive regulation

Major cannabis companies experienced their most impressive weekly performance of the year following an FDA announcement regarding CBD product enforcement. The regulatory shift propelled leading cannabis stocks significantly higher and positioned the sector for its strongest weekly showing in months.

In a Wednesday correspondence, FDA Commissioner Marty Makary indicated the agency would refrain from enforcing specific sections of the Federal Food, Drug, and Cosmetic Act against hemp-sourced oral products solely due to CBD content. This enforcement discretion extends to items marketed as dietary supplements and products administered under physician supervision.

Cannabidiol, or CBD, represents a non-intoxicating component of cannabis plants. Consumers utilize it for various wellness applications, and it appears in numerous health and lifestyle products.

The cannabis sector’s upward momentum started Tuesday, preceding the White House and FDA’s launch of a four-part meeting series with industry representatives to address CBD compliance and enforcement strategies.

This FDA policy shift complements President Trump’s December executive action, which rescheduled marijuana from Schedule I to Schedule III classification under federal drug regulations. That directive also tasked the FDA, National Institutes of Health, and Centers for Medicare and Medicaid Services with developing pathways to broaden CBD access for therapeutic applications.

Cannabis equities experienced a temporary boost following December’s executive order before retracing gains. The industry continues to grapple with challenges including limited banking services, stock exchange listing restrictions, and interstate trade barriers stemming from federal regulations.

Tilray Brands

Tilray emerged as a standout performer during this week’s rally. Shares climbed 6.7% in Thursday’s session alone, positioning it among the sector’s highest by dollar volume. The enterprise conducts research, cultivation, processing, and distribution of medical cannabis throughout numerous nations including Canada, Germany, Australia, and Argentina.


TLRY Stock Card
Tilray Brands, Inc., TLRY

Canopy Growth

Canopy Growth advanced 2.6% during Thursday trading. The organization markets cannabis and hemp-based products for recreational and therapeutic purposes across the US, Canada, Germany, and additional global markets. Its operations include the Storz and Bickel division, which manufactures cannabis vaporization devices. Canopy joined Tilray as one of the week’s most actively traded cannabis equities.


CGC Stock Card
Canopy Growth Corporation, CGC

Curaleaf Holdings

Curaleaf delivered the most impressive gains among major cannabis companies Thursday, surging 8.4%. This domestically-focused cannabis enterprise has captured significant investor attention as market participants monitor potential federal policy changes that could enable cross-state commerce for cannabis operations.

The AdvisorShares Pure US Cannabis exchange-traded fund climbed 4.6% Thursday and advanced 16% across the week, tracking toward its strongest weekly gain since December.

An industry expert observed the policy represents a “narrowly scoped” approach that falls short of establishing a comprehensive framework for the wider cannabis marketplace, urging Congressional legislative action.

The FDA conducted its initial stakeholder discussion on CBD policy Wednesday, with three additional sessions planned in the continuing series.

The post FDA CBD Policy Shift Triggers Massive Rally in Cannabis Stocks appeared first on Blockonomi.

시장 기회
Major 로고
Major 가격(MAJOR)
$0.03568
$0.03568$0.03568
+0.22%
USD
Major (MAJOR) 실시간 가격 차트

World Cup Combo: Aim for 200x

World Cup Combo: Aim for 200xWorld Cup Combo: Aim for 200x

Combine up to 20 World Cup matches in one order

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

Score Your Share of 50K USDT

Score Your Share of 50K USDTScore Your Share of 50K USDT

Complete DEX+ tasks to unlock the Champion Wheel